Andrew Defilippis MD, MSc

Dr. DeFilippis is a translational researcher leveraging his expertise in cohort development, clinical cardiology, cardiovascular epidemiology, and acute myocardial infarction (MI) to better understand, diagnose, and predict the full spectrum of myocardial injury events, specifically subtypes of MI. Dr. DeFilippis is a board-certified cardiologist and Medical Director of the Cardiovascular Intensive Care Unit at Vanderbilt. Dr. Defilippis has significant experience evaluating cardiovascular risk prediction in the Multi-Ethnic Study of Atherosclerosis (MESA) and serves on the MESA Project and Publication Committee. Dr. DeFilippis also has significant experience in acute MI diagnosis, treatment, and research. He serves on the steering committee for the NIH-sponsored multicenter Myocardial Ischemia and Transfusion (MINT) trial. Dr. DeFilippis has adjudicated over 800 cases for the presence of acute MI as part of a diagnostic of a point-of-care troponin assay seeking FDA approval. Dr. DeFilippis’ work has been published in multiple peer-reviewed journals, including Annals of Internal Medicine, The Lancet, and the Journal of the American College of Cardiology. He recently published an invited Viewpoint in Circulation Research, “Myocardial Infarction as a Clinical Endpoint in Research—What Are We Really Talking About?” and a White Paper in Circulation, “Assessment and Treatment of Patients with Type 2 Myocardial Infarction and Acute Non-Ischemic Myocardial Injury.” Dr. DeFilippis is the principal investigator on NIH, foundation, and industry grants and works with an international team of collaborators on innovative projects to advance our ability to more effectively prevent, diagnose, and treat cardiovascular disease.